The effect of chemotherapy combined with dendritic cells-cytotoxic T lymphocytes cells in patients with non-small cell lung cancer
Author(s): Liu Zejie, Song Yilin, Yang Jing, Li Junqiang, Feng Yingming, Su Haichuan
Pages: 1899-1903
Year: 2017 Issue: 12
Journal: Journal of Modern Oncology
Keyword: non-small cell lung cancer(NSCLC); chemotherapy; cytotoxic T lymphocytes(CTL) cells; dendritic cells(DC);
Abstract: Objective:To analyze the activity and safety of the therapy that chemotherapy combined with dendritic cells and cytotoxic lymphocytes(DC-CTL) cells in patients with non-small cell lung cancer(NSCLC).Methods:We collected 114 patients from our hospital who were pathological diagnosised Ⅰb-Ⅳ stage non-small cell lung cancer(NSCLC) during 2013-05 to 2015-12,20 cases of postoperative chemotherapy combined DC-CTL group and 32 cases of postoperative chemotherapy group,23 cases of chemotherapy combined DC-CTL group and 39 cases of chemotherapy group.Retraspectively analyse the clinical characteristics of 114 patients,including the disease control rates(DCR),median disease free survival(M-DFS),median progression free survival(M-PFS),side effects.Patients were followed until November 2016.Results:1 year of DCR:Postoperative chemotherapy combine with DC-CTL group(75.0%) vs postoperative chemotherapy group(43.8%)(P=0.044).M-DFS of postoperative chemotherapy combined DC-CTL group(19.5 months) was significantly longer than the postoperative chemotherapy group(11.5 months)(P=0.025 5).Side effects of DC-CTL were significantly lower than chemotherapy.Conclusion:Postoperative chemotherapy combined with DC-CTL can slow disease progression of NSCLC patients and prolong disease free survival safely.
Pages: 1899-1903
Year: 2017 Issue: 12
Journal: Journal of Modern Oncology
Keyword: non-small cell lung cancer(NSCLC); chemotherapy; cytotoxic T lymphocytes(CTL) cells; dendritic cells(DC);
Abstract: Objective:To analyze the activity and safety of the therapy that chemotherapy combined with dendritic cells and cytotoxic lymphocytes(DC-CTL) cells in patients with non-small cell lung cancer(NSCLC).Methods:We collected 114 patients from our hospital who were pathological diagnosised Ⅰb-Ⅳ stage non-small cell lung cancer(NSCLC) during 2013-05 to 2015-12,20 cases of postoperative chemotherapy combined DC-CTL group and 32 cases of postoperative chemotherapy group,23 cases of chemotherapy combined DC-CTL group and 39 cases of chemotherapy group.Retraspectively analyse the clinical characteristics of 114 patients,including the disease control rates(DCR),median disease free survival(M-DFS),median progression free survival(M-PFS),side effects.Patients were followed until November 2016.Results:1 year of DCR:Postoperative chemotherapy combine with DC-CTL group(75.0%) vs postoperative chemotherapy group(43.8%)(P=0.044).M-DFS of postoperative chemotherapy combined DC-CTL group(19.5 months) was significantly longer than the postoperative chemotherapy group(11.5 months)(P=0.025 5).Side effects of DC-CTL were significantly lower than chemotherapy.Conclusion:Postoperative chemotherapy combined with DC-CTL can slow disease progression of NSCLC patients and prolong disease free survival safely.
Related Articles